Five-Year Follow Up of Genotypic Resistance Patterns in HIV-1 Subtype C Infected Patients in Botswana after Failure of Thymidine Analogue-Based Regimens

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Doualla-Bell, Florence, Tendani Gaolathe, Ava Avalos, Suzanne Cloutier, Ndwapi Ndwapi, Christina Holcroft, Howard Moffat, et al. 2009. Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens. Journal of the International AIDS Society 12:25.

Published Version
doi:10.1186/1758-2652-12-25

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:4551788

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens

Florence Doualla-Bell1, Tendani Gaolathe2,3, Ava Avalos4, Suzanne Cloutier4, Ndwapi Ndwapi4, Christina Holcroft5, Howard Moffat4, Diana Dickinson6, Max Essex2,7, Mark A Wainberg*1 and Madisa Mine2,4

Address: 1McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada, 2Botswana-Harvard School of Public Health, AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana, 3Infectious Disease Care Clinic, Princess Marina Hospital, Gaborone, Botswana, 4Ministry of Health of Botswana, Botswana, 5Statistical Consultation Service, Centre for Clinical Epidemiology and Community Studies, Jewish General Hospital Montreal, Quebec, Canada, 6Independence Surgery, Gaborone, Botswana and 7Harvard School of Public Health, Boston, Massachusetts, USA

Email: Florence Doualla-Bell - def87@hotmail.com; Tendani Gaolathe - tendanig@yahoo.com; Ava Avalos - avaavalos@gmail.com; Suzanne Cloutier - suzcloutier@yahoo.com; Ndwapi Ndwapi - ndwapi@it.bw; Christina Holcroft - cholcroft2@yahoo.com; Howard Moffat - hmmoffat@gov.bw; Diana Dickinson - dbd@intclinic.co.bw; Max Essex - messex@hsph.harvard.edu; Mark A Wainberg* - mark.wainberg@mcgill.ca; Madisa Mine - mmine@bhp.org.bw

* Corresponding author

Abstract

Objective: Our objective was to establish genotypic resistance profiles among the 4% of Botswana patients who experienced virologic failure while being followed within Botswana’s National Antiretroviral Treatment Program between 2002 and 2007.

Methods: At the beginning of the national program in 2002, almost all patients received stavudine (d4T), together with didanosine (ddI), as part of their first nucleoside reverse transcriptase inhibitor (NRTI)-based regimen (Group 1). In contrast, the standard of care for all patients subsequently enrolled (2002-2007) included zidovudine/lamivudine (ZDV/3TC) (Group 2). Genotypes were analyzed in 26 patients from Group 1 and 37 patients from Group 2. Associations between mutations were determined using Pearson’s correlation coefficient and Jaccard’s coefficient of similarity.

Results: Seventy-eight percent of genotyped patients possessed mutations associated with protease inhibitor (PI) resistance while 87% and 90%, respectively, exhibited mutations associated with NRTIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The most frequent PI mutations involving resistance to NFV were L90M (25.2%) and D30N (16.2%), but mutations at positions K45Q and D30N were often observed in tandem (P = 0.002; Group 2) alongside Q61E in 42.8% of patients who received ZDV/3TC. Both major patterns of thymidine analogue mutations, TAM 1 (48%) and TAM 2 (59%), were represented in patients from Group 1 and 2, although M184V was higher among individuals who had initially received ddI (61% versus 40.5%). In contrast, L74V was more frequent among individuals from Group 2 (16.2% versus 7.7%). Differences in regard to NNRTI mutations were also observed between Group 1 and Group 2 patients.

Conclusion: Despite a low rate of therapeutic failure (4%) among these patients, those who failed possessed high numbers of resistance mutations as well as novel resistance mutations and/or polymorphisms at sites within reverse transcriptase and protease.

Published: 25 October 2009

Journal of the International AIDS Society 2009, 12:25 doi:10.1186/1758-2652-12-25

Received: 2 July 2009
Accepted: 25 October 2009

This article is available from: http://www.jiasociety.org/content/12/1/25

© 2009 Doualla-Bell et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Botswana has an approximate 30% seroprevalence for HIV-1 [1] and was also one of the first African countries to provide universal free access to antiretroviral therapy (ART) in 2002. Prior to 2002, most patients in Botswana initiated therapy with d4T/ddI-based regimens. From January 2002, the main first-line regimen in Botswana was ZDV/3TC plus either efavirenz (EFV) or nevirapine (NVP) in women in whom pregnancy was likely to occur. For patients failing initial regimens, the main second-line regimen was d4T/ddI plus nelfinavir (NFV). More recently, lopinavir/ritonavir (LPV/r) has been approved for use in second-line to replace NFV, while tenofovir (TDF)/3TC is now used as a nucleoside reverse transcriptase inhibitor (NRTI) backbone in first-line [2].

By March 2007, 84,927 patients had entered the national ART programme, while an additional 9,514 had been followed in the private sector. The percentage of patients receiving therapy is estimated to be greater than 80% of the total need [3]. As of April 2007, a total of 17,400 patients had been registered at the Adult Infectious Disease Care Clinic (IDCC) located at the Princess Marina Hospital in Gaborone. Among these, approximately 11,000 were receiving comprehensive HIV treatment and care. This site has also launched a treatment failure protocol that has ascertained the treatment failure rate among ARV patients to be 4% [4].

Both acquired [5] and transmitted [6] drug resistance represent obstacles for the long-term use of ARVs. Previous publications from the IDCC described the frequencies and patterns of mutations in the reverse transcriptase (RT) and protease (PR) genes [7-9]. In general, no major impact of HIV subtypes has been observed regarding drug susceptibility [10,11].

We previously demonstrated that d4T/ddI-based regimens were associated with high rates of selection of the K65R mutation in HIV-1 subtype C [8,12]. For purposes of this analysis, patients failing therapy have been divided into those who received d4T/ddI as part of their first regimen (Group 1) versus those who initiated therapy with ZDV/3TC and who received ddI as part of second or subsequent regimens (Group 2). We also attempted to delineate associations between different mutations that are involved in drug resistance, as has already been calculated in subtype B viruses [13-15].

Methods

Patients and HIV-1 subtype C sequencing

Among the 4% of Batswana patients who experienced treatment failure at the IDCC, 363 received a ddI-based regimen as part of their first (Group 1) or second or subsequent regimen (Group 2). As recommended by the Botswana national programme since March 2005, all patients experiencing virological failure after their second-line regimen, mostly containing NFV as a PI were evaluated by genotyping, viz., a total of 63 patients (27 in Group 1 and 36 in Group 2).

These genotypes were linked to patients’ demographic, immunologic, virologic and therapeutic clinical data. HIV genotyping for drug resistance was performed on plasma samples using a commercially available kit (ViroSeq HIV-1 genotyping system; Abbott Laboratories). All the patients were confirmed as possessing subtype C viruses on the basis of nucleotide sequence alignment using the ClustalX-version 1.8 sequencing tool [16]. The neighbour-joining method was employed for phylogenetic tree building using the NJplot programme.

Statistical and mutational covariate analysis

We first calculated the frequencies of RT and PR mutations in the pol sequences of 26 Group 1 and 37 Group 2 patients who were followed. We also established relationships between the presence of specific mutations using both the Pearson correlation coefficient (P) and the Jaccard similarity coefficient (J). A Fisher’s exact test was also performed to assess the significance of any associations that were found. As a reference, we employed the 2008 IAS-USA list of mutations [17].

Results

Patient characteristics

The characteristics of the 63 patients followed in this study are shown in Table 1, with virologic failure being defined as the inability to suppress plasma viremia or the rebound of viral load (VL) on at least two consecutive occasions to levels >400 copies RNA/ml. Median CD4 cell counts at failure were 334 cells/mm³ for Group 1 and 233 cells/mm³ for Group 2 and medians of viral loads (log10 HIV-1 RNA copies/ml) were 4.2 and 4.7 for Group 1 and 2, respectively, at which time most patients had received three different treatment regimens.

Mutations to protease inhibitors

Phylogenetic analysis indicated that all of the 63 patients who were genotyped possessed subtype C viruses. Approximately 78% of PI-treated individuals exhibited resistance mutations; similar patterns of resistance were observed among both groups (Figure 1). Among patients who received NFV, the most common mutations observed were D30N and L90M, consistent with previous results (Table 2).

Interestingly, 43% of patients possessed a Q61E mutation (CAA → GAA) that emerges from a silent substitution, i.e., CAA in subtype C relative to CAG in subtype B. The I62V resistance mutation was present in 11% of those patients.
who only received NFV as a PI. We confirmed the correlation seen by others between D30N and K45Q (P = 60, J = 50; p = 0.002; Group 2), while L89I was only found in association with D30N (P = 50.5, J = 50; p = 0.002; Group 2) (Table 3).

**Mutations to reverse transcriptase inhibitors**

Approximately 87% of the patients who were genotyped possessed mutations associated with resistance to NNRTIs, while 90% presented with mutations associated with NRTIs (Table 4, Figure 2). Some individuals in Group 2 possessed I202V, L228R/H and D324E substitutions. M184V was observed in 16 of 26 Group 1 patients, 14 of whom had received 3TC prior to genotyping. In patients from Groups 1 and 2, both TAM 1 (48%) and TAM 2 (59%) mutations were present.

Similarly, 10 of 15 Group 2 patients who possessed M184V had been on a 3TC-containing regimen at the time of testing. Only two patients carried the K65R mutation; one of these had received TDF and the other had received ddI at the time of genotyping. The length of time on ineffective regimens (based on non-suppressed VL) was 809 days and 279 days for Groups 1 and 2, respectively.

Patients with the L74V mutation (16.2% in Group 2) were on ABC/ddI at the time of genotyping. In the group of patients who received EFV, the most frequent mutations

### Table 1: Characteristics of the 63 patients who received ddI/d4T (Group 1) versus ZDV/3TC (Group 2) as first-line therapy

|                              | Group 1 (n = 26) | Group 2 (n = 37) |
|------------------------------|------------------|------------------|
| **Age (years)**              |                  |                  |
| Median                       | 35               | 34               |
| Interquartile range          | [24-57]          | [21-48]          |
| **Female sex (%)**           |                  |                  |
|                              | 61.5             | 60.7             |
| **Baseline nadir CD4 cell count** |                  |                  |
| Median                       | 96               | 61               |
| Interquartile range          | [2-276]          | [1-317]          |
| **CD4 cell count at failure visit** |                |                  |
| Median                       | 334              | 233              |
| Interquartile range          | [41-937]         | [9-1313]         |
| **Log10 HIV-1 RNA at failure visit** |                |                  |
| Median                       | 4.2              | 4.7              |
| Interquartile range          | [2.9-5.33]       | [3.5-5.9]        |
| **Total days on antiretroviral therapy at the time of genotype** |                |                  |
| Median Interquartile range   | 998              | 486              |
| Interquartile range          | [228-2507]       | [59-1346]        |
| **Total time (days) to non-detectability of viral load (<400 copies/ml) at the time of genotype** |                |                  |
| Median                       | 158              | 96               |
| Interquartile range          | [28-1693]        | [10-1188]        |
| **Average number of ARV regimens received by the time of genotype** |                |                  |
|                              | 3*               | 2.5†             |

*Group 1 - ARV regimens received by the time of genotyping. ddI/d4T/NVP, ZDV/3TC/EFV, ddI/d4T/NVP, ZDV/3TC/NVP, d4T/3TC/NVP, ABC/ddI/NVP, ddI/d4T/NVP, ddl/ZDV, ddI/d4T/EFV, ZDV/3TC/NVP, ddl/ZDV/3TC, ZDV/3TC/NVP, ABC/ddI/NVP, ddl/d4T/EFV, ZDV/3TC/EFV, ddI/d4T/NVP, ZDV/3TC/NVP (n = 2); ddI/d4T, ZDV/3TC/NVP, ddl/TDF/LPV; ddl/d4T/EFV, ZDV/3TC/EFV (n = 3); ddl/ZDV, ZDV/3TC/NVP, ddl/d4T/EFV; ddl/d4T/NVP, ZDV/3TC/NVP, LPVr/SQV; ddl/ZDV/NVP, 3TC/d4T/EFV; ddl/d4T, ZDV/3TC/EFV, ddl/d4T/EFV, ZDV/3TC/EFV, ABC/ddI/NVP, ddl/d4T/EFV/LPV; ddl/d4T/EFV, ABC/ddI/NVP, d4T/3TC/EFV; ddl/ZDV/NVP, d4T/3TC/IDV, ddl/d4T/EFV.

†Group 2 - ARV regimens received by the time of genotyping. ZDV/3TC/NVP, ZDV/3TC/NVP, ddl/d4T/NVP, ZDV/3TC/NVP, 3TC/ddI/NVP, 3TC/ddI, ZDV/3TC/NVP, ddl/d4T/EFV, ZDV/3TC/EFV, ddl/d4T/EFV, ABC/ddI/NVP, ddl/d4T/EFV/LPV; ddl/d4T/EFV, ABC/ddI/NVP, d4T/3TC/EFV; ddl/ZDV/NVP, d4T/3TC/IDV, ddl/d4T/EFV.
Figure 1

**Frequency of HIV-1 subtype C protease mutations.**

**A** - The frequency of amino acid mutations in HIV-1 subtype C (white) or B (black) protease in drug-naïve patients are reported based on the Stanford HIV drug resistance database.

**B** - Amino acids in HIV-1 subtype C protease of Batswana treated patients from Group 1 (white) or Group 2 (black) are reported. Where more than one amino acid change may have occurred, the most prevalent amino acid is underlined.
were K103N, V106M and I135V/T, while Y181C and G190A were more frequent among patients who received NVP. In Group 2 patients, the Y181C and A98S/G mutations were found in association with the L228R/H mutation, \((I = 66.6, p = 0.0001)\) and \((I = 41.7, p = 0.009)\), respectively, while L228R/H was associated with G190A in Group 1 patients (Table 5). We also observed an association between H221Y and Y181C in Group 1 patients treated with NVP.

### Discussion

This study provides data on drug resistance mutational profiles in HIV-1 subtype C-infected Batswana patients who experienced treatment failure between 2002 and 2007. Among novel findings, we have shown that resistance to NFV in these patients seems to involve the K45Q mutation in association with D30N, and occurs with similar frequency \((I = 50, p = 0.002)\) as that previously characterized between D30N and N88D \((I = 33.3, p = 0.01)\). The L89I mutation was also associated with D30N, suggesting that it may occur early in the establishment of resistance to NFV. Accumulation of large numbers of PI mutations may reflect the duration of time that patients may have been left on a failing regimen [18].

We previously demonstrated a greater propensity for patients infected by HIV-1 subtype C to develop the K65R mutation after treatment with ddI-based regimens in first-line therapy [8]. More recently, high rates of K65R were also observed among patients from West Africa who received 3TC/d4T/NNRTI as a first-line regimen [19,20]. High rates of virologic failure have also been reported in patients with the K65R mutation compared to L74V [21,22]. Both the L74V and K65R mutations may impact on subsequent TDF responses in patients who had previously received ddl [22].

Clearly, these two nucleoside cross-resistance mutations may compromise a wide array of future nucleoside-based therapeutic options in treatment-experienced patients. In the present study, the frequency of the K65R mutation was low (two of 26 patients). One possible explanation may be the reversion of the K65R mutation after use of subsequent ARV regimens, due to considerations of low viral fitness. This phenomenon emphasizes the need for more sensitive assays that can be used for surveillance of resistance mutations.

The high frequency of NNRTI mutations is also disturbing and raises questions about their use in first-line regimens in developing countries, where financial constraints may often compel physicians to keep patients on failing regimens for longer than desirable. In this context, it might be interesting to conduct a study such as ACTG 5142 [23], which compared the use of EFV to a first-line PI, in settings where subtype C viruses are predominant.

We also observed several associations involving less common resistance mutations, such as L228R/H and Y181C \((I = 66.6, p = 0.0001)\) and A98S/G \((I = 41.7, p = 0.009)\) in Group 2 patients and L228R/H in association with G190A in Group 1. We further observed a preferential emergence of the H221Y mutation in Group 1 NVP-treated patients, who first exhibited the Y181C mutation. Moreover, mutations at positions A98, K101, V106, E138, Y181 and G190 were discovered, and it is not yet known whether these substitutions will affect clinical responsiveness to new NNRTIs, such as etravirine (ETV), in HIV-1 subtype C infections [24]. A review article on the subject of HIV drug resistance mutations and viral subtypes has recently been published [25].

Switching from ZDV/3TC to d4T/ddI (Group 2) and subsequent maintenance on a suboptimal NVP-containing regimen may also have resulted in higher rates of association between G190A and TAMs or G190A and L74V. Oth-

---

**Table 2: Frequency of mutations within PR**

| Mutations | Frequency (%) | ²P value |
|-----------|--------------|----------|
| L10F/I   | 23           | 0.23     |
| K20R/T/I/M | 34.6       | 0.07     |
| D30N     | 19.2         | 0.43     |
| E35D/N   | 50           | 0.31     |
| K45Q     | 3.8          | 0.12     |
| M46I     | 7.7          | 0.19     |
| D60E     | 23           | 0.43     |
| Q61E/D   | 19           | 0.06     |
| I62V     | 0            | 0.11     |
| N88D     | 11.5         | 0.48     |
| N88S     | 7.7          | 0.51     |
| L89M     | 57.7         | 0.51     |
| L89I     | 19.2         | 0.39     |
| L90M     | 15           | 0.34     |

²P value: probability of significant differences between groups

---

**Notes:**

- L10F/I, V106M and I135V/T, while Y181C and G190A were more frequent among patients who received NVP. In Group 2 patients, the Y181C and A98S/G mutations were found in association with the L228R/H mutation, \((I = 66.6, p = 0.0001)\) and \((I = 41.7, p = 0.009)\), respectively, while L228R/H was associated with G190A in Group 1 patients (Table 5). We also observed an association between H221Y and Y181C in Group 1 patients treated with NVP.
ers have shown the co-presence of L74V and Y181C in patients who failed a NVP-containing regimen [26].

Although the Botswana ARV national programme has tried to optimize ARV therapy and has changed first- and second-line regimens to TDF/FTC/NNRTI and ZT/3TC/LPV/r, respectively, our results remain relevant for other developing country settings that still use ineffective combinations in a context of poor adherence. Indeed, it is important to understand genotypic resistance patterns in developing countries where treatment options may be more limited than those that are available wealthier countries and in which different viral subtypes may predominate. Associations such as those between the D30N and K45Q mutations in PR have not previously been reported. It is likely that the use of suboptimal therapy may facilitate the emergence of novel resistance pathways and that this will become a major concern in resource-limited settings.

**Conclusion**

HIV subtype C-infected patients in Botswana who began therapy with either d4T/ddI- or ZDV/3TC-based regimens and who failed therapy have developed drug resistance-associated mutations at high frequency. These mutations are associated with resistance against each of NRTIs, NNRTIs, and PIs and include several novel substitutions relative to those typically observed with subtype B viruses. Hopefully, the current use of improved treatment regimens in Botswana will mitigate both rates of treatment failure as well as the future development and transmission of HIV.

| Mutations | Correlated mutations | Pearson coeff. | Jaccard coeff. | P value (freq cell) |
|-----------|----------------------|----------------|----------------|-------------------|
|           | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 |
| L10F/I   | K20R/T/I/M | M46I | 36.9 | 36.7 | 36.4 | 33.3 | 0.13 (15.4) | 0.07 (13.5) |
| D30N     | A71V | 42.8 | 37.1 | 37.5 | 28.5 | 0.06 (11.5) | 0.04 (10.8) |
| Q61E/D   | T74S | 65.9 | 44.4 | 57.1 | 43.7 | 0.005 (15.4) | 0.02 (0.02) |
| T74S     | T74S | 65.9 | 40.36 | 50 | 23 | 0.008 (11.5) | 0.04 (8.1) |
| N88D     | N88I | 52 | | | | | |
| N88S     | | 0.08 (11.5) | 0.04 (8.1) |
| K20R/T/I/M | E35D/N | E35D/N | 40.4 | 50.1 | 46.7 | 65.4 | 0.10 (26.9) | 0.006 (45.9) |
| M46I     | K45Q | 39.7 | 38.4 | 0 | 28.5 | 0.11 (7.7) | 0.03 (16.2) |
| T74S     | V77I | 39.7 | | | | |
| N88S     | 39.7 | | | 0.11 (7.7) | 0.11 (7.7) |
| D30N     | K45Q | 41 | 60.5 | 20 | 50 | 0.19 (3.85) | 0.002 (13.5) |
| N88D     | N88I | 74 | 52.4 | 60 | 33.3 | 0.004 (11.5) | 0.01 (8.1) |
| L89I     | 50.5 | 42.8 | | | | |
| E35D/N   | T74S | 48.8 | 38.5 | | | 0.04 (19.2) | |
| M46I     | A71V | 41.5 | 33.3 | 0.04 (8.1) | 0.04 (8.1) |
| V77I     | 41.5 | 33.3 | 0.04 (8.1) | 0.04 (8.1) |
| D60E     | Q61E/D | 48.6 | 50 | 0.005 (24.32) | 0.03 (7.7) |
| Q61E/D   | N88S | 59 | 40 | | | |
Figure 2
Frequency of HIV-1 subtype C reverse transcriptase mutations. A - The frequency of amino acid mutations in HIV-1 subtype C (white) or B (black) reverse transcriptase in drug-naive patients are reported based on the Stanford HIV drug resistance database. B - Amino acids in HIV-1 subtype C reverse transcriptase of Batswana treated patients from Group 1 (white) or Group 2 (black) are reported. Where more than one amino acid change may have occurred, the most prevalent amino acid is underlined.
**Table 4: Frequency of mutations within RT.**

| Mutations | Frequency (%) | *P value | Group 1 | Group 2 |
|-----------|---------------|----------|---------|---------|
| **NNRTI** |               |          |         |         |
| A98S/G    | 26.9          | 18.9     | -       |         |
| K101E/Q/P/R | 19.23      | 21.6     | -       |         |
| K103N     | 34.6          | 48.6     | -       |         |
| V106M     | 30.8          | 16.21    | -       |         |
| V108I     | 15.4          | 18.9     | -       |         |
| E138A     | 15.4          | 27       | -       |         |
| V179E/D   | 15.3          | 13.5     | -       |         |
| Y181C     | 23            | 27       | -       |         |
| Y188L     | 0             | 13.5     | -       |         |
| G190A     | 23            | 13.5     | -       |         |
| **NRTI (non-TAM)** |     |          |         |         |
| K65R      | 7.7           | 0        | -       |         |
| S68G      | 19.2          | 8.1      | -       |         |
| L74V/I    | 7.7           | 16.2     | -       |         |
| Q151M     | 3.8           | 2.7      | -       |         |
| M184V     | 61            | 40.5     | -       |         |
| **TAM1**  |               |          |         |         |
| 41L       | 26.9          | 40.5     | -       |         |
| 210W      | 19.2          | 18.9     | -       |         |
| 215Y      | 26.9          | 29.7     | -       |         |
| **TAM2**  |               |          |         |         |
| 67N       | 46            | 67.56    | 0.07    |         |
| 70R       | 35            | 37.8     | -       |         |
| 215F      | 26.9          | 29.7     | -       |         |
| 219Q      | 34.6          | 37.8     | -       |         |

*P value: probability of significant differences between groups

**Table 4: Frequency of mutations within RT. (Continued)**

| Others | Frequency (%) | *P value |
|--------|---------------|----------|
| E53D   | 11.5          | 13.5     | -       |
| K102R/Q/Q/N | 15.4        | 0        | -       |
| I135V/T | 30.8          | 45.9     | -       |
| T139A/P/S | 0             | 16.2     | -       |
| I142V/T | 15.4          | 8.1      | -       |
| A158S  | 23            | 0        | -       |
| S162C/G/A/T | 15.4       | 24.3     | -       |
| I178L/M | 19            | 35       | -       |
| I202V  | 34.6          | 8        | 0.008   |
| E203A/K/D | 3.8           | 18.9     | -       |
| H221Y  | 11.5          | 18.9     | -       |
| L228R/H | 8             | 27       | 0.05    |
| D250E  | 42.3          | 40.5     | -       |
| K275R/Q | 23            | 8        | 0.09    |
| D324E  | 27            | 8        | 0.04    |

*P value: probability of significant differences between groups
Table 5: Significant correlations of pairs of mutations within RT.

| Group 1 | Pearson coeff. | Jaccard coeff. | P value | Group 2 | Pearson coeff. | Jaccard coeff. | P value |
|---------|----------------|----------------|---------|---------|----------------|----------------|---------|
| 101E/190A | 65.92 | 57.1 | 0.005 | 101E/190A | 36.8 | 30 | 0.06 |
| 101E/219Q | 46.55 | 40 | 0.034 | 106M/139A | 40.32 | 33.3 | 0.04 |
| 102R/53D | 51.3 | 40 | 0.05 | 106M/138A | 39.3 | 33.3 | 0.04 |
| 103N/178L | 46 | 40 | 0.03 | 106M/179E | 46.9 | 37.5 | 0.02 |
| 106M/283I | 63.9 | 50 | 0.005 | 1081/208Y | 49.85 | 37.5 | 0.02 |
| 190A/69D | 65.9 | 50 | 0.008 | 181C/67N | 42.2 | 40 | 0.01 |
| 142V/158S | 52.5 | 42.8 | 0.03 | 181C/69D | 64.9 | 50 | 0.001 |
| 178L/135V | 52.5 | 44.4 | 0.02 | 181C/98S | 63.8 | 54.5 | 0.001 |
| 221Y/162C | 51.3 | 40 | 0.05 | 190A/41L | 47.9 | 33.3 | 0.007 |
| 221Y/181C | 66 | 50 | 0.008 | 190A/210W | 41.5 | 33.3 | 0.04 |
| 228R/190A | 52.7 | 33.3 | 0.05 | 190A/215Y | 46.9 | 37.5 | 0.02 |
| 251D/53D | 58.4 | 60 | 0.004 | 190A/74L | 46.9 | 37.5 | 0.02 |
| 278N/60I | 62.3 | 50 | 0.03 | 228R/98S | 48 | 41.7 | 0.009 |
| 283I/102R | 70.4 | 60 | 0.006 | 228R/215F | 40 | 40 | 0.04 |
| 294T/102R | 67.7 | 50 | 0.02 | 210W/215Y | 44.07 | 38.4 | ND |
| 210W/215Y | 36.4 | 33.3 | ND | 41L/215Y | 42.64 | 44.4 | ND |
| 41L/215Y | 41.3 | 40 | ND | 41L/210W | 44.4 | 37.5 | ND |
| 41L/210W | 36.4 | 33.3 | ND | 41L/53D | 31.7 | 25 | ND |
| 41L/53D | 59.5 | 42.8 | ND | 41L/74V/I | 53 | 40 | ND |
| 67N/70R | 62.37 | 61.5 | ND | 67N/70R | 54.05 | 56 | ND |
| 70R/219Q | 83.01 | 80 | ND | 70R/219Q | 65.53 | 64.7 | ND |
| 219Q/67D | 62.37 | 61.5 | ND | 219Q/67D | 54.05 | 56 | ND |
| 215F/67D | 40.85 | 35.7 | ND | 215F/67D | 45.06 | 44 | ND |
| 215F/70R | 36.9 | 33.3 | ND | 215F/70R | 34.6 | 38.9 | ND |
| 219Q/69N/D | 49.64 | 33.3 | ND | 219Q/69N/D | 34.36 | 27 | ND |

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
FDB wrote the initial draft of this manuscript and was largely responsible for compilation and interpretation of results. TG and AA helped draft the paper and manage data. SC and CH contributed data to the paper, while NN, HM, and ME corrected the paper and provided supervision. MM directed the laboratory in which sequencing results were obtained. MAW corrected the manuscript, provided interpretation of data, and collated results.

Acknowledgements
We thank the Botswana Ministry of Health for encouragement (study approved by the National Health Research Development Committee of the Botswana Ministry of Health), Mpho Zwinila for database management, and the Service of Infectious Diseases at the IDCC, Princess Marina Hospital, Gaborone, Botswana, for its contribution to this work. This study was funded by grants from the Secure the Future programme of Bristol-Myers Squibb, Inc, the National Institutes of Health (USA) and the Canadian Institutes of Health Research.

References
1. WHO/UNAIDS: AIDS epidemic update 2007 [http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf].
2. Botswana National HIV/AIDS Treatment Guidelines: 2008 Version MASA Antiretroviral Therapy. Department of HIV/AIDS Prevention and Care: 2008.
3. 2008 Botswana progress report of the national report to UNGASS: Declaration of commitment on HIV/AIDS Ministry of State President-National AIDS Coordinating Agency.
4. Avalos A, Gaolathe T, Cloutier S, Ndwapi N, Doualla-Bell F, Mosepele M, Zwanila M, Moffat H, Seipone K, Wainberg M: Botswana’s ART failure management: A 5-year review of the Infectious Disease Care Clinic at Princess Marina Hospital. 15th Conference on Retroviruses and Opportunistic Infections [Abstract 836]. Boston 2008.
5. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
6. Brenner BG, Roger M, Routy JP, Moisi D, Ntengwana M, Matte C, Baril JG, Thomas R, Rouleau D, Bruneau J, Leblanc R, Leguizamón P, Tremblay C, Charest H, Wainberg MA, Quebec Primary HIV Infection Study Group: High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007, 195:951-959.
7. Doualla-Bell F, Gaseitsiwe S, Ndungu T, Modukanele M, Peter T, Novisky V, Ndewa N, Tendani G, Avalos A, Wester W, Busman H, Cardiello P, Marlink R, Moffat H, Thior I, Wainberg MA, Essex M: Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother 2004, 15:189-200.
8. Avalos A, Gaolathe T, Cloutier S, Novitsky V, Mosepele M, Seipone K, Moffat H, Essex M, Wainberg MA.
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-4185.

9. Doualla-Bell F, Avalos A, Gaolathe T, Mine M, Gaseitsiwe S, Ndawapi N, Novitsky VA, Brenner B, Oliveira M, Moisi D, Moffat H, Thior I, Essex M, Wainberg MA: Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nevirapin-containing regimen. Antimicrob Agents Chemother 2006; 50:2210-2213.

10. Kantor R: Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 2006, 19:594-606.

11. Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004, 31:215-220.

12. Johnson BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006, 20:F9-F13.

13. Ceccherini-Silberstein F, Svircher Y, Sing T, Artese A, Santoro MM, Felicetti F, Bertolli A, Alcaro S, Palmara G, d’Arminio Monforte A, Balzarini J, Antinori A, Lengauer T, Perno CF: Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 2007, 81:11507-11159.

14. Svircher Y, Sing T, Santoro MM, Fortici F, Rodriguez-Barrios F, Bertolli A, Beerweninkel N, Bellucchi MC, Gago F, d’Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF: Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006, 80:7186-7198.

15. Rhee SY, Liu TF, Holmes SP, Shafer RW: HIV-1 Subtype B Protease and Reverse Transcriptase Amino Acid Covariation. PLoS Comput Biol 2007, 3(5):e87.

16. Thompson JD, Gibson TJ, Plewinski F, Jeanninougin F, Higgins DG: The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997, 25:4876-4882.

17. Johnson VA, Brun-Vezinet F, Glanzer B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD: Update of the Drug Resistance Mutations in HIV-1: Spring 2008. Top HIV Med 2008, 16:62-68.

18. Kagan RM, Cheung PK, Huard TK, Lewinski MA: Increasing prevalence of HIV-1 protease-associated mutations correlates with long-term non-suppressive protease inhibitor treatment. Antiviral Res 2006, 71:42-52.

19. Hosseinipour M, van Oosterhout J, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus S, Nelson J, Eron J, Kumwenda J: The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009, 23:1127-1134.

20. Wallis CL, Bell C, Boulme R, Sanne I, Venter F, Papathanasopoulos M, Stevens W: Emerging ART Drug Resistance in Subtype C: Experience from 2 Clinics in Johannesburg, South Africa. 14th Conference of Retroviruses and Opportunistic Infections. Los Angeles, CA, USA 2007.

21. Waters L, Nelson M, Mandala S, Bower M, Powles T, Gazzard B, Stebbing J: The risks and incidence of K65R and L74V mutations and subsequent virologic responses. Clin Infect Dis 2008, 46:96-100.

22. Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, Borroto-Esoda K, Miller MD: Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr 2007, 46:174-180.

23. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Britz B, Laloo UG, Murphy RL, Swindells S, Hvlid D, Mellors JW, AIDS Clinical Trials Group Study A5142 Team: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358:2095-2106.

24. Llibre JM, Santos JR, Puig T, Molto J, Ruiz R, Closet B: Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz [Abstract 65]. Antiv Ther 2007, 12:1574.

25. Martinez-Cajigas JL, Pai NP, Klein MB, Wainberg MA: Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009, 12:11.

26. Svircher Y, Sing T, Santoro MM, Bertolli A, Gori C, Artese A, Alcaro S, d’Arminio Monforte A, Antinori A, Lengauer T, Perno CF, Ceccherini-Silberstein F: Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of NNRTI resistance. XV International HIV Drug Resistance Workshop [Abstract 149]. Sitges, Spain 2006.